Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 552 clinical trials
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial)

additional 1-year follow-up. The primary outcome is 2-year conversion rate of psychosis. Secondary outcomes include 1-year conversion rate of psychosis, the severity and duration of prodromal symptoms

  • 25 Jan, 2021
  • 11 locations
Targeted Cognitive Training in Clinical High Risk (CHR) for Psychosis

/young adults at clinical high risk (CHR) for psychosis. TCT is designed to optimize learning-induced neuroplasticity in vulnerable neurocognitive systems. A main aim is to test the hypothesis that this

  • 22 Jan, 2021
  • 2 locations
SRC Inhibition as a Potential Target for Parkinson's Disease Psychosis

approval of a drug called Pimavanserin as a treatment for PD psychosis in the USA. Based on other recent studies, we believe that Saracatinib, a drug that interacts within the same system as Pimavanserin

  • 24 Jan, 2021
  • 1 location
Glutamatergic Mechanisms of Psychosis and Target Engagement (SA1)

50 healthy volunteers (HV) will participate in 2 identical ketamine-induced pharmacoBOLD (phBOLD) sessions at least 7 days apart. On both days, clinical assessments will be performed following removal of the subject from the scanner. HV will be discharged home after clearance by the study physician. This study will assign ketamine …

  • 28 Jan, 2021
  • 1 location
A Randomized Controlled Trial of Individual Therapy for First Episode Psychosis

In the first year of treatment after a FE of SCZ, 75% to 90% of patients achieve remission from psychotic symptoms. However, approximately 40% of FE patients are non-adherent to

schizoaffective disorder
psychotic symptoms
cognitive therapy
  • 07 Nov, 2020
  • 1 location
Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia

disorder may be effective at reducing psychosis or altering the course of the disease, there are currently no biomarkers capable of identifying subjects in early stages of SZ who are likely to respond to

  • 24 Jan, 2021
  • 1 location
Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial

Program" (IEP) and "Metacognitive Training for Psychosis" (MCT), in relation to each other, and in relation to "Treatment As Usual" (TAU). It is hypothesized that at the end of therapy, compared to

  • 22 Jan, 2021
  • 1 location
Randomized Controlled Trial of Aspirin vs Placebo in the Treatment of Pre-psychosis

The primary objective of this study is to determine whether aspirin is effective in alleviating symptoms of the clinical high risk (CHR) syndrome for psychosis. The investigators further aim to

  • 23 Jan, 2021
  • 1 location
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis

To assess the effect of pimavanserin on the activities of daily living in subjects with Parkinson's Disease Psychosis

  • 05 Mar, 2021
  • 29 locations
Fluoxetine vs Aripiprazole Comparative Trial (FACT)

We are conducting a randomized, 24-week, double-blind study, comparing fluoxetine with aripiprazole in 48 patients with attenuated positive symptoms at a level of at least moderate severity.

  • 24 Feb, 2021
  • 1 location